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background or short axis > 10 mm on PET-CT were considered 
pathologic. Nodes between 5-10 mm were considered 
pathologic if the nodes had an irregular shape/border, had 
lost its architecture or were inhomogeneous. Eight patients 
were treated with lymphadenectomy prior to chemo-
radiation and did not receive a nodal boost. The remaining 75 
patients had a total number of 214 nodes boosted by EBRT 
(PTV-N) either as a simultaneous integrated boost (SIB) or as 
a sequential boost to 55-60Gy. The elective whole pelvic 
target (PTV-E) was treated to 45-50 Gy (Table 1). PTV-E was 
extended to the para-aortic region (PAN) in case of 
pathological nodes in the common iliac region or higher. 
Concomitant Cisplatin was given to 95% of the patients. MRI 
was performed 3 and 12 months after completion of 
treatment in all patients, 82/140 of the patients also had a 
PET-CT at 3 months follow-up. Additional imaging was 
performed on clinical indication. The total dose to PTV-N was 
calculated by rigidly registration of dose maps from elective 
EBRT, EBRT boost and IGABT to the planning CT scan. All 
doses were converted to EQD2 by the linear quadratic model 
(α/β = 10, repair halftime 1.5 h). 
 
Results: Pathological lymph node volume was on average 1.5 
cm3 (range 0.1-44.9) and average total dose was 62.4 Gy 
EQD2 (range 51.0-69.1). At a median follow-up time of 28 
months (range 3-64) five recurrences were diagnosed inside 
PTV-N. Each recurrent node was in a different patient. There 
was no significant impact of nodal dose for nodes receiving 
above or below 60 Gy EQD2 (Fischer's exact test, p=0.6) nor 
did we find any significance of nodal volume. (Figure 1). Two 
of the node positive patients had a new nodal recurrence 
within the PTV-E. One patient had multiple recurrences 
involving PTV-N, PTV-E, as well as distant metastases. Two of 
the node positive patients had recurrences in both PTV-E and 
outside in the PAN region. None of the 57 node negative 
patients experienced nodal recurrence in PTV-E. Nine 
patients (6%) recurred in PAN outside PTV-E without any 
other sites of recurrence. Four of these patients did not have 
nodal disease at time of diagnosis.  
Conclusions: Both micro- and macroscopic nodal control in 
locally advanced cervical cancer is high with the currently 
used treatment schedules. Recurrences are mainly located 
outside the PTV in the PAN region. Due to the limited number 
of recurrences in boosted nodes it has not been possible to 
establish a dose response relationship. 
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Purpose/Objective: Volumetric Modulated Arc Therapy 
RapidArc® (VMAT) has shown to be able to maintain a good 
toxicity profile in pelvic irradiation (PRT). We present our 
experience in treating pelvis for post-operative endometrial 
cancer (EC) with VMAT and simultaneous integrated boost 
(SIB) on vaginal cuff in patients (pts) unable to receive 
vaginal brachytherapy (VB). 
Materials and Methods: From September 2011 to December 
2013, fifty consecutive pts, submitted to hysterectomy with 
bilateral salpingo-oophorectomy and pelvic 
lymphadenectomy for EC, were candidate to PRT and VB +/- 
chemotherapy, according to stratification risk category. All 
the pts recruited refused VB for logistic problems or because 
unable or not willing to receive such treatment. After a 
specific informed consent, a dose of 54 Gy to the pelvis and 
66 Gy to the vaginal cuff in 30 fractions was delivered with 
SIB-VMAT technique. A 5 mm trans-vaginal probe and 
Magnetic Resonance Imaging were used to define vaginal 
cuff. All toxicity data were collected according to CTCAE 
v4.0; clinical outcomes were analyzed retrospectively.  
Results: Median FUP was 36 months (range, 12 to 39 months). 
According to FIGO 2009, the most representative stages 
were: IB1 (20% - 10/50), IB2 (28% - 14/50), IIA2 (16% - 8/50), IIB 
(6% - 3/50), IIIA (2% - 1/50), IIIC (28% - 14/50). The 2-year-OS 
and 2-year-LC were 96% and 100%. The 3-year-OS and LC 
were 96% and 87%. The median DFS was 25 months (range, 
12-30). No vaginal-cuff recurrence was registered. The only 
two loco-regional failures were pelvic-LNs metastases. Acute 
GI toxicity was registered as follow: G0 in 6 pts, G1 in 26 pts, 
G2 in 18 pts. No case of toxicity ≥ G3 was observed. Acute GU 
toxicity was: G0 in 5 pts, G1 in 21 pts, G2 in 24 pts. No case 
of toxicity ≥ G3 was observed. No late moderate - severe GI 
or GU toxicities were reported. A statistical correlation was 
found between acute G2 GI toxicity with Intestinal Cavity (IC) 
dose-constraints V20 Gy ≥ 30% (p-value = 0.02), V20 ≥ 40% (p 
= 0.02), V30 ≥ 30% (p = 0.004) and with IC-Dmax ≥ 45 Gy (p = 
0.001). Regarding GU assessment, the risk to develop G2 
acute toxicity is 3 times higher with adjuvant chemotherapy 
(p = 0.07).  
Conclusions: In EC pts unable to receive VB or refusing to 
receive this treatment, SIB-VMAT could be a viable 
alternative. The present analyses showed promising findings. 
Further prospective studies are advocated.  
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